Alterity Pushes ATH434 Toward Phase 3 With New MSA Disease-Modifying Signals

Alterity Therapeutics has presented new imaging, biomarker, and clinical findings that reinforce the development of ATH434 for Multiple System Atrophy (MSA). The data, shared across three scientific meetings, highlight the company’s biomarker-driven approach to a rare neurodegenerative disease with no approved disease-modifying therapies.

According to CEO David Stamler, M.D., the analyses strengthen evidence that ATH434 may slow disease progression, with advanced MRI methods and biomarker-based patient stratification helping to optimize the design of the upcoming Phase 3 program.

At the 2026 ISMRM and ISMRT Annual Meeting, Paula Trujillo reported that quantitative susceptibility mapping (QSM) MRI detected progressive iron accumulation in early-stage MSA. Using data from Alterity’s bioMUSE natural history study alongside Parkinson’s disease and healthy control datasets, researchers showed that QSM may identify MSA before clinical diagnosis, track disease progression, and standardize imaging assessments across multicenter trials. These findings support MRI-based biomarkers as tools for patient enrichment and endpoint validation in future studies.

Further analyses from the ATH434-201 Phase 2 trial were presented at the Movement Disorder Society of Australia and New Zealand Scientific Meeting by Daniel Claassen. Results demonstrated that ATH434 50 mg twice daily slowed functional decline on the Unified Multiple System Atrophy Rating Scale (UMSARS) Part I by approximately 48% compared with placebo (p=0.035).

Combined active treatment groups also showed significant slowing of progression (p=0.047). Higher baseline cerebrospinal fluid neurofilament light chain (CSF NfL) levels predicted greater clinical worsening, supporting its role as a prognostic biomarker and a potential stratification tool for Phase 3. MRI analyses further suggested reduced iron accumulation in affected brain regions, consistent with ATH434’s proposed iron-chaperone mechanism.

At the 2026 MSA Symposium hosted by University College London, investigators reported that ATH434 reduced progression of swallowing impairment over 52 weeks. Placebo-treated patients experienced greater worsening on the Swallowing Disturbance Questionnaire, while the 50 mg dose achieved statistical significance (p=0.003). Because swallowing dysfunction is a major contributor to morbidity in MSA, these findings underscore the potential quality-of-life benefits of ATH434 alongside biomarker and imaging signals.

Collectively, these results support Alterity’s strategy of integrating imaging, fluid biomarkers, and functional outcomes into the next stage of ATH434 development. By demonstrating signals of slowed disease progression and refining patient selection and endpoint sensitivity, the analyses provide a strong foundation for the planned Phase 3 trial.

ATH434, an oral investigational therapy designed to reduce iron accumulation and abnormal protein aggregation, has received Fast Track Designation from the U.S. Food and Drug Administration and Orphan Drug Designation from both the FDA and European Commission for MSA.

Reference

ASX:ATH – Alterity Data Supports ATH434 Phase 3 Advancement in MSA